Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Department of Thoracic and Cardiovascular Surgery, The Second Affiliated Hospital of Nantong University, Nantong 226001, China.
Biomed Res Int. 2020 Jan 11;2020:1648419. doi: 10.1155/2020/1648419. eCollection 2020.
Abnormal expression of neuroepithelial cell transforming gene 1 (NET1) has been authenticated in many human cancers, including lung cancer. We have previously reported that NET1 functioned as an oncogene and promoted human non-small-cell lung cancer (NSCLC) growth and migration. However, the correlation between NET1 and its upstream miRNAs needed further illustration. Our present work demonstrated that miR-22 had a relatively low expression, and NET1 had a relatively high expression in both NSCLC samples and lung adenocarcinoma cell lines compared with corresponding normal controls. Moreover, miR-22 directly regulated NET1 and was verified to weaken cancer cell proliferation and migration, as well as enhance cell apoptosis by suppressing NET1. Furthermore, the inhibitory effect of miR-22 can be reversed via overexpressing NET1 using an ectopic expression vector in NSCLC cells. Our findings showed that miR-22/NET-1 axis may contribute to the inhibition of NSCLC growth and migration and represents a promising therapeutic target for NSCLC.
神经上皮细胞转化基因 1(NET1)的异常表达已在许多人类癌症中得到证实,包括肺癌。我们之前的研究表明,NET1 是一种癌基因,可促进人非小细胞肺癌(NSCLC)的生长和迁移。然而,NET1 与其上游 miRNA 之间的相关性仍需要进一步阐明。我们的研究表明,miR-22 在 NSCLC 样本和肺腺癌细胞系中的表达相对较低,而 NET1 的表达相对较高,与相应的正常对照相比。此外,miR-22 可直接调控 NET1,并通过抑制 NET1 减弱癌细胞的增殖和迁移,促进细胞凋亡。此外,通过在 NSCLC 细胞中转染 NET1 的过表达载体,可逆转 miR-22 的抑制作用。我们的研究结果表明,miR-22/NET-1 轴可能有助于抑制 NSCLC 的生长和迁移,是 NSCLC 治疗的一个有前途的靶点。